2022
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. PLOS ONE 2022, 17: e0275648. PMID: 36206298, PMCID: PMC9543876, DOI: 10.1371/journal.pone.0275648.Peer-Reviewed Original ResearchConceptsNeurological side effectsSide effectsBreast cancerTaxane exposureProgressive neurological changesTaxane-based chemotherapyNon-interventional studyWeeks of treatmentEnd of treatmentIrreversible side effectsCourse of treatmentQuality of lifeTaxane therapyPeripheral neuropathyProspective studyPeripheral bloodBlood levelsCancer survivalNeuronal viabilityNeurological changesEffective treatmentChemotherapyCognitive impairmentPatientsPotential protein biomarkers
2013
Novel Functional Assay for Spindle-Assembly Checkpoint by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient
Torikoshi Y, Gohda K, Davis ML, Symmans WF, Pusztai L, Kazansky A, Nakayama S, Yoshida T, Matsushima T, Hortobagyi GN, Ishihara H, Kim SJ, Noguchi S, Ueno NT. Novel Functional Assay for Spindle-Assembly Checkpoint by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient. Journal Of Cancer 2013, 4: 697-702. PMID: 24312139, PMCID: PMC3842438, DOI: 10.7150/jca.6248.Peer-Reviewed Original ResearchTaxane-containing chemotherapyClinical responsePreoperative chemotherapyTaxane-induced cell deathAnthracycline-based treatmentFine-needle aspiration biopsyLarge prospective studiesBreast cancer patientsCyclin-dependent kinase 1Taxane-resistant tumorsLogistic regression analysisTaxane-containing therapyBreast tumor patientsDysfunction groupTaxane therapyPathologic responseProspective studyCancer patientsPredictive biomarkersTumor patientsBreast cancerClinicopathologic parametersAspiration biopsyBiopsy samplesPatients
2001
Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond
Esteva F, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar A, Hortobagyi G. Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. The Oncologist 2001, 6: 133-146. PMID: 11306725, DOI: 10.1634/theoncologist.6-2-133.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerHER-2/neu proteinAnthracycline/taxane combinationsDevelopment of anthracyclineAdvanced breast cancerHigh-dose chemotherapyPrimary breast cancerSingle-agent activityCombination chemotherapy treatmentsNovel biologic therapiesNovel treatment approachesMultidrug resistance inhibitorsTopoisomerase I inhibitorTaxane therapyBiologic therapyPalliative therapyTaxane combinationsProlong survivalTumor supressor geneChemotherapy treatmentTreatment approachesFluoropyrimidine analogsPatientsNeu protein